PALO ALTO, Calif., Feb. 1, 2016 /PRNewswire/ -- ConfometRx is pleased to announce that it has succeeded in elucidating the crystallographic structure of a novel GPCR-G protein complex composed of a Family A GPCR coupled to its G protein. G protein coupled receptors (GPCRs) are the largest family of signaling proteins in the human genome. They are involved in virtually all physiological processes and represent the single largest target class for medicines on the market. This discovery, only the second reported GPCR-G protein complex, was achieved within the research agreement with biopharma UCB to gain insight into the design of differentiated drugs.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels. Follow us on Twitter: @UCB_news.
ConfometRx, a leader in G protein coupled receptor (GPCR) structural characterization and analysis, has exclusive rights to the patented fusion-protein technology used to solve at least 25 novel GPCR structures. This pioneering technology was developed by Stanford Professor and ConfometRx co-founder, Dr. Brian Kobilka, and Stanford University has been awarded six separate patents on this fundamental technology with other patents still pending both in the U.S. and abroad. Please feel free to reach out to firstname.lastname@example.org.